SPAC1093.02 Antibody

What is the SPAC1093.02 protein in S. pombe and why is it significant for research?

SPAC1093.02 is a protein encoded in the genome of Schizosaccharomyces pombe (fission yeast strain 972 / ATCC 24843). This protein is of interest to researchers studying fundamental cellular processes in eukaryotic organisms. S. pombe has emerged as an important model organism for investigating cell cycle regulation, gene expression, and other conserved cellular mechanisms due to its genetic tractability and similarities to higher eukaryotes. Understanding SPAC1093.02's function contributes to our broader knowledge of conserved cellular pathways across species. Experimental approaches to characterize this protein typically include gene deletion/mutation studies, localization analyses, and interaction studies using the corresponding antibody as a detection tool .

How does the SPAC1093.02 antibody compare with other fission yeast antibodies in terms of specificity?

The SPAC1093.02 antibody belongs to a collection of research antibodies targeting various S. pombe proteins. When comparing antibody specificity across fission yeast targets, researchers should evaluate several parameters: cross-reactivity with related proteins, background signal in immunological assays, and performance across different experimental conditions. Western blot analysis using wild-type versus knockout strains represents a gold standard for specificity validation. Unlike antibodies targeting highly conserved proteins (such as tubulin or actin), protein-specific antibodies like SPAC1093.02 typically demonstrate higher target specificity but may require more extensive validation. Researchers should compare immunoblot profiles when evaluating specificity, looking specifically for single bands at the predicted molecular weight in wild-type samples and absent bands in knockout strains .

What are the fundamental differences between monoclonal and polyclonal SPAC1093.02 antibodies?

The fundamental differences between monoclonal and polyclonal SPAC1093.02 antibodies reflect broader principles in antibody science:

How should researchers optimize Western blot protocols specifically for SPAC1093.02 antibody?

Optimizing Western blot protocols for SPAC1093.02 antibody requires systematic adjustment of several parameters:

• Sample preparation: For S. pombe proteins, the extraction method significantly impacts results. Use either the TCA precipitation method (more stringent) or glass bead lysis (gentler) depending on protein solubility. Include protease inhibitors freshly prepared before extraction.

• Gel percentage selection: For SPAC1093.02 protein detection, select the appropriate acrylamide percentage based on the molecular weight (typically 10-12% for medium-sized proteins).

• Transfer optimization: For yeast proteins, semi-dry transfers at 15V for 30 minutes often yield better results than wet transfers. Use PVDF membranes rather than nitrocellulose for higher protein retention.

• Blocking conditions: Test both 5% non-fat milk and 3% BSA in TBST as blocking agents, as some antibodies perform differently with each blocker.

• Antibody dilution: Begin with 1:1000 dilution and adjust based on signal-to-noise ratio. For SPAC1093.02 antibody, overnight incubation at 4°C often produces cleaner results than short incubations at room temperature.

• Validation controls: Always include a wild-type versus knockout strain comparison to confirm specificity. Additionally, include a loading control antibody (like anti-PSTAIR for Cdc2) to normalize expression levels .

What are the recommended protocols for using SPAC1093.02 antibody in immunofluorescence studies?

For optimal immunofluorescence studies with SPAC1093.02 antibody in fission yeast:

• Cell fixation: Fix exponentially growing S. pombe cells with 3.7% formaldehyde for 30 minutes, as methanol fixation may compromise some epitopes. For membrane-associated proteins, a combined formaldehyde/methanol approach may yield better results.

• Cell wall digestion: Treat fixed cells with Zymolyase-100T (1mg/ml) for 10-30 minutes to permeabilize the cell wall. Monitor digestion microscopically to prevent over-digestion.

• Permeabilization: Use 1% Triton X-100 for 5 minutes to ensure antibody access to intracellular targets.

• Blocking: Block with 5% BSA in PBS for 1 hour to reduce non-specific binding.

• Primary antibody incubation: Apply SPAC1093.02 antibody at 1:100-1:500 dilution (determined empirically) and incubate overnight at 4°C.

• Secondary antibody selection: Choose secondary antibodies with minimal cross-reactivity to yeast proteins. Pre-adsorbed antibodies designed for fungal applications significantly reduce background.

• Counterstaining: DAPI (1μg/ml) counterstaining for nuclear visualization helps contextualize the target protein's localization pattern.

• Controls: Include both technical controls (secondary-only) and biological controls (knockout strains) to validate specificity of observed signals .

How can researchers effectively use SPAC1093.02 antibody for chromatin immunoprecipitation (ChIP) experiments?

For effective ChIP experiments using SPAC1093.02 antibody in fission yeast:

• Crosslinking optimization: For yeast cells, use 1% formaldehyde for 15 minutes at room temperature, followed by quenching with 125mM glycine. The crosslinking time may need adjustment based on the target protein's chromatin association strength.

• Chromatin fragmentation: Sonicate to achieve fragments of approximately 200-500bp. For S. pombe, 12-15 cycles (30 seconds on/30 seconds off) at medium power typically yields appropriate fragmentation. Verify fragment size by agarose gel electrophoresis.

• Pre-clearing: Pre-clear chromatin with Protein A/G beads for 1 hour to reduce non-specific binding.

• Antibody binding: Use 2-5μg of SPAC1093.02 antibody per ChIP reaction. Include an IgG control and, if possible, a ChIP using an epitope-tagged version of SPAC1093.02 as positive control.

• Washing stringency: For yeast ChIP, use increasingly stringent washes (low salt, high salt, LiCl, and TE buffer) to reduce background.

• Elution and reversal: Elute complexes with 1% SDS buffer at 65°C, then reverse crosslinks overnight at 65°C.

• DNA purification: Purify DNA using phenol-chloroform extraction followed by ethanol precipitation, or commercial ChIP DNA purification kits.

• Validation: Validate ChIP enrichment by qPCR targeting predicted binding regions before proceeding to genome-wide analyses like ChIP-seq .

What are the essential validation steps for confirming SPAC1093.02 antibody specificity in S. pombe?

Essential validation steps for confirming SPAC1093.02 antibody specificity include:

• Genetic validation: Compare antibody reactivity between wild-type S. pombe and SPAC1093.02Δ deletion strains using Western blot. A specific antibody will show a band at the expected molecular weight in wild-type samples that is absent in the deletion strain.

• Epitope-tagged validation: Compare detection patterns between endogenous protein (using the antibody) and epitope-tagged version (using anti-tag antibody) to confirm correlation.

• Mass spectrometry verification: Perform immunoprecipitation followed by mass spectrometry analysis to confirm that the antibody pulls down SPAC1093.02 protein.

• Peptide competition assay: Pre-incubate the antibody with excess purified antigen peptide before application to samples. Specific binding should be blocked, resulting in signal reduction.

• Cross-species reactivity assessment: Test reactivity against related proteins from other species (e.g., S. cerevisiae, human) to evaluate potential cross-reactivity.

• siRNA/gene silencing: In systems supporting RNAi, compare antibody signal in control versus SPAC1093.02 siRNA-treated samples to confirm signal specificity .

How should researchers interpret unexpected bands when using SPAC1093.02 antibody in Western blots?

When encountering unexpected bands with SPAC1093.02 antibody:

• Post-translational modification analysis: Additional bands at higher molecular weights may represent phosphorylated, ubiquitinated, or otherwise modified forms of SPAC1093.02. Treat samples with phosphatase or deubiquitinating enzymes to confirm.

• Degradation assessment: Lower molecular weight bands may indicate proteolytic degradation. Adjust sample preparation by adding protease inhibitors, reducing handling time, or maintaining lower temperatures throughout preparation.

• Splice variant investigation: Unexpected bands might represent alternative splice forms. Verify using RT-PCR to identify potential transcript variants.

• Cross-reactivity evaluation: Use knockout/deletion strains to determine if unexpected bands persist in the absence of SPAC1093.02, which would indicate cross-reactivity.

• Antibody validation: Consider testing another lot of the antibody or a different antibody against the same target to determine if the unexpected bands are antibody-specific artifacts.

• Sample condition assessment: Evaluate whether sample buffer composition, heating conditions, or reduction status affects band patterns.

• Technical considerations: Check for gel overloading, incomplete transfer, or contamination in the Western blot system that might contribute to artifact bands .

What techniques can validate SPAC1093.02 antibody performance in immunoprecipitation experiments?

To validate SPAC1093.02 antibody performance in immunoprecipitation:

• IP-Western validation: After immunoprecipitation, perform Western blotting using the same or different SPAC1093.02 antibody (if available) to confirm target capture. The immunoprecipitated sample should show enrichment compared to input.

• Mass spectrometry confirmation: Subject immunoprecipitated material to mass spectrometry analysis to verify the presence of SPAC1093.02 and identify potential interacting partners.

• Reverse IP validation: If SPAC1093.02 is thought to interact with specific partners, perform reverse immunoprecipitation using antibodies against these partners, then detect SPAC1093.02.

• Epitope-tagged control: Compare immunoprecipitation efficiency between the antibody and anti-tag antibodies using strains expressing epitope-tagged SPAC1093.02.

• Negative controls: Include immunoprecipitation with non-specific IgG and with SPAC1093.02 knockout/knockdown samples to confirm specificity.

• Crosslinking optimization: Test different crosslinking conditions to optimize complex preservation while maintaining antibody accessibility to epitopes.

• Quantitative comparison: Use quantitative proteomics to measure enrichment factors for SPAC1093.02 versus background proteins in immunoprecipitation samples .

How can researchers address epitope masking issues when SPAC1093.02 interacts with protein complexes?

Addressing epitope masking in protein complex studies:

• Epitope mapping: Determine which region of SPAC1093.02 the antibody recognizes and cross-reference with protein interaction domains. Consider using antibodies targeting different epitopes if available.

• Mild denaturation protocols: Implement partial denaturation (using low SDS concentrations or mild heat treatment) to expose masked epitopes while preserving important interactions.

• Crosslinking strategies: Use reversible crosslinkers to stabilize complexes, then partially reverse the crosslinking before antibody application to improve epitope accessibility.

• Proximity labeling approaches: Instead of direct detection, consider BioID or APEX2 proximity labeling approaches where SPAC1093.02 is tagged with a promiscuous biotin ligase to label proximal proteins.

• Native versus denaturing conditions: Compare antibody performance under native versus denaturing conditions to assess epitope accessibility.

• Alternative detection strategies: For completely masked epitopes, consider detecting known interaction partners as proxies for SPAC1093.02 presence.

• Structural biology integration: When possible, integrate antibody epitope information with structural data (from crystallography or cryo-EM) to predict and address potential masking issues .

What advanced approaches can resolve contradictory results when using SPAC1093.02 antibody across different experimental platforms?

When facing contradictory results across platforms:

• Systematic buffer compatibility analysis: Create a matrix of buffer conditions used across different applications (Western blot, IP, IF) and systematically test antibody performance across these conditions to identify optimal parameters.

• Epitope accessibility assessment: Different experimental conditions may affect epitope exposure. Test mild denaturation, alternative fixation methods, or different detergents to standardize epitope accessibility.

• Sample preparation standardization: Develop a unified sample preparation protocol that works across platforms, focusing on preserving the target protein's native state consistently.

• Multiple antibody validation: Use multiple antibodies targeting different epitopes of SPAC1093.02 to confirm results.

• Orthogonal detection methods: Implement non-antibody-based detection methods (mass spectrometry, CRISPR tagging) to validate contradictory findings.

• Conditional expression systems: Use controlled expression systems to validate antibody performance against varying protein levels.

• Advanced imaging approaches: For localization discrepancies, employ super-resolution microscopy or correlative light and electron microscopy to resolve fine-scale details that might explain contradictions .

How should researchers design experiments to investigate SPAC1093.02 protein dynamics during cell cycle progression?

For investigating SPAC1093.02 dynamics during the cell cycle:

• Synchronization protocol selection: For S. pombe, use temperature-sensitive cdc25 mutants, nitrogen starvation/release, or hydroxyurea block/release to achieve population synchrony. Validate synchronization by measuring septation index or DNA content by flow cytometry.

• Time-resolved sampling: Collect samples at 10-15 minute intervals spanning a complete cell cycle (approximately 2.5-3 hours for S. pombe at 30°C).

• Multi-parameter analysis: Simultaneously measure:

  • SPAC1093.02 protein levels by Western blot

  • Phosphorylation status using phospho-specific antibodies or Phos-tag gels

  • Subcellular localization by immunofluorescence microscopy

  • Protein-protein interactions by co-immunoprecipitation

• Reference proteins: Include analysis of established cell cycle markers (Cdc13/Cyclin B, Cdc2/CDK1, Cut2/Securin) to accurately map SPAC1093.02 dynamics to specific cell cycle phases.

• Single-cell analysis: Complement population-based approaches with single-cell immunofluorescence to account for cell-to-cell variability.

• Perturbation experiments: Use temperature-sensitive cell cycle mutants or specific inhibitors to arrest cells at different cell cycle stages and analyze SPAC1093.02 status.

• Quantitative image analysis: Develop automated image analysis pipelines to quantify localization changes across hundreds of cells for statistical power .

What statistical approaches are most appropriate for quantifying SPAC1093.02 expression levels across experimental conditions?

Appropriate statistical approaches for quantifying SPAC1093.02 expression:

• Normalization strategy selection: For Western blot data, normalize SPAC1093.02 signal to appropriate loading controls (e.g., PSTAIR/Cdc2, α-tubulin, or total protein via Ponceau staining). For housekeeping proteins that might vary under experimental conditions, total protein normalization is preferred.

• Technical replicate handling: Average technical replicates (minimum three) before performing statistical tests, ensuring signal measurements fall within the linear dynamic range of detection.

• Statistical test selection:

  • For comparing two conditions: Student's t-test (parametric) or Mann-Whitney U test (non-parametric)

  • For multiple conditions: One-way ANOVA with appropriate post-hoc tests (Tukey or Dunnett)

  • For time-course experiments: Repeated measures ANOVA or mixed-effects models

• Effect size calculation: Report Cohen's d or similar effect size metrics alongside p-values to quantify the magnitude of observed differences.

• Variability representation: Present data as box plots or violin plots rather than simple bar graphs to convey data distribution information.

• Outlier handling: Define objective criteria for outlier identification (e.g., ±2.5 SD from mean) and explicitly state outlier handling procedures.

• Power analysis: Conduct a priori power analysis to determine appropriate sample sizes for detecting expected effect sizes with sufficient statistical power (typically 0.8 or higher) .

How can researchers effectively troubleshoot non-specific background issues with SPAC1093.02 antibody in immunohistochemistry?

To troubleshoot non-specific background in immunohistochemistry:

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers) and concentrations (3-10%) to reduce non-specific binding. For yeast samples, adding 0.1% Tween-20 to blocking buffer often improves specificity.

• Antibody dilution titration: Perform systematic dilution series (1:50 to 1:2000) to identify optimal concentration balancing specific signal and background.

• Pre-adsorption protocol: Pre-incubate diluted antibody with S. cerevisiae lysate (if working with S. pombe) to remove cross-reactive antibodies.

• Fixation modification: Compare different fixation protocols (paraformaldehyde, methanol, acetone) as epitope accessibility and background can vary significantly.

• Endogenous peroxidase/phosphatase quenching: If using enzymatic detection, optimize peroxidase/phosphatase quenching steps to reduce endogenous activity.

• Secondary antibody selection: Test secondary antibodies from different manufacturers and species to minimize cross-reactivity.

• Washing optimization: Increase washing duration and detergent concentration in wash buffers to remove non-specifically bound antibodies.

• Antigen retrieval comparison: Compare different antigen retrieval methods (heat-induced vs. enzymatic) to improve specific signal while minimizing background .

What analytical frameworks help distinguish between direct and indirect effects when studying SPAC1093.02 protein interactions?

Analytical frameworks for distinguishing direct and indirect protein interactions:

How should researchers integrate multiple antibody-based techniques to create comprehensive models of SPAC1093.02 function?

Creating comprehensive functional models of SPAC1093.02 requires strategic integration of multiple antibody-based approaches:

• Multi-scale experimental design: Structure investigations to span from molecular (protein-protein interactions, post-translational modifications) to cellular (localization, dynamics) to systems (phenotypic outcomes) levels, using the SPAC1093.02 antibody as a common detection tool.

• Temporal profiling framework: Establish a timeline of SPAC1093.02 activity across relevant biological processes (cell cycle, stress response, etc.) using time-course experiments with consistent sampling intervals.

• Perturbation-response mapping: Systematically perturb the system (genetic modifications, environmental stresses) and measure changes in SPAC1093.02 status using a consistent panel of antibody-based assays.

• Data integration pipelines: Develop computational workflows to integrate diverse data types (Western blot quantification, immunofluorescence intensity/localization, interactome maps) into unified models.

• Validation through orthogonal approaches: Confirm key findings using non-antibody methods (genetic interaction screens, transcriptomics) to overcome potential antibody-specific artifacts.

• Model refinement cycle: Implement an iterative approach where model predictions guide further targeted experiments, with results feeding back to refine the model.

• Comparative analysis framework: Extend findings by comparing SPAC1093.02 function with orthologous proteins in related species, using similar antibody-based approaches to highlight evolutionary conservation and divergence .